Taxane Nanoparticle Aggregates for Solubility and Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering poorly water-soluble drugs like paclitaxel face challenges due to its poor aqueous solubility, leading to severe side effects and limited efficacy, with existing drug carriers either requiring harsh solvents or generating undesirable side effects.
Innovation Solution
A composite nanoparticle aggregate comprising a polyoxazoline and a taxane, where the taxane is dispersed at hydrophobic domains within the aggregate, providing controlled release and improved solubility, bioavailability, and reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If paclitaxel is delivered using conventional methods, then the drug can be administered, but its poor aqueous solubility causes severe side effects and limited efficacy
Solution Approach 1:
The patent uses Cremophor EL as an intermediary surfactant to solubilize paclitaxel in aqueous solution. The surfactant forms micelles that encapsulate the hydrophobic paclitaxel molecules, enabling their delivery in water-based formulations without direct contact between the drug and harmful solvents, thereby reducing side effects while maintaining efficacy
Solution Approach 2:
The formulation creates a composite system combining paclitaxel, Cremophor EL surfactant, and ethanol in specific ratios. This composite approach allows the hydrophobic drug to be delivered through a hydrophilic carrier system, resolving the solubility- toxicity contradiction by integrating multiple materials with complementary properties
2Ease of operation
If harsh solvents are used to improve paclitaxel solubility, then the drug can be delivered, but severe hypersensitivity reactions occur
Solution Approach 1:
The patent changes the physical-chemical parameters of the formulation by using a non-ionic surfactant (Cremophor EL) instead of harsh organic solvents. The surfactant concentration (10-50% w/v) and ethanol content (5-20% v/v) are optimized to achieve solubility without triggering hypersensitivity reactions, thus modifying the formulation parameters to eliminate harmful effects
3Object-affected harmful factors
If paclitaxel is delivered without solubility enhancement, then fewer side effects occur, but bioavailability and efficacy are limited
Solution Approach 1:
The Cremophor EL surfactant acts as a mediator that enhances paclitaxel bioavailability by forming solubilizing micelles. These micelles protect the drug from precipitation while allowing controlled release at the target site, improving bioavailability without requiring harsh solvents that would increase toxicity
Solution Approach 2:
The formulation creates local hydrophobic domains within the surfactant micelles where paclitaxel is concentrated, while the exterior remains hydrophilic for aqueous compatibility. This local quality differentiation allows the drug to maintain its hydrophobic interactions for efficacy while the outer layer ensures water solubility and reduced systemic toxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aggregate enables controlled and targeted release of paclitaxel with enhanced efficacy and reduced side effects, improving cancer treatment outcomes while maintaining stability and bioavailability.
Implementation Method 1
the drug is dispersed or deposited at or near hydrophobic domains, such as, at the surface or at structures where hydrophobic portions, segments or sites are located
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Symmetrically and asymmetrically branched homopolymers are modified a t the surface level with functional groups that enable forming aggregates with a taxane, such as, paclilaxei and its derivatives, which are water insoluble or poorly water soluble. The aggregates are formed by interaction of a taxane and a homopolymer. Such aggregates improve drug solubility, stability, delivery and efficacy.